Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.49

+3.7%

10:19 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (16774)	5/13/2005 7:40:59 PM
From: zeta1961	Read Replies (1) of 52153

Wick was suggesting that some of the PRs in this trial were pushing 90% or above reduction in tumour size Caught that too.. Peter, cherry picking?..they are in season out here<g> Seriously, I think one can reverse that and say, what are the chances of gathering 13 patients and one of them having a CR and most having a PR? It's when I look at this study in light of previous results and this year's AACR re: MOA's that reinforce my bullishness of the molecule.. eidt: as Wick said, "the number will be the number when the larger trial data come in"..chuckle..I happen to appreciate his blunt-ness and impatience with the analyst community Wonder what route they'll use to finance larger first line trial.. Zeta

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next